Sioux accelerates commercialization of Xyall’s tumor dissection solution with capital investment
Medtech innovator Xyall attracts €6M Series B funding to further expand its molecular pathology solutions and make them available to the market on a larger scale. The funding comes from existing investors such as the Brabant Development Agency (BOM) and Sioux Technologies, a consortium led by Health Investment Partners (HIP) and several private investors.
Sioux Technologies presents a medical revolution
Sioux Technologies joined forces with Xyall, a leading MedTech innovator in molecular pathology, to create a high-tech solution for automating tissue dissection, for molecular diagnostics. Watch the video
Software and mathware are changing the world
What does it take to be successful in the global and dynamic power play of the tech industry? Who better to ask this question than Risto Siilasmaa. He directed the miracle of Nokia, which went down dramatically in the violence of the smartphone industry but rose again as a global player in network infrastructure.
Sioux builds second multidisciplinary system house in China
Pioneering is in our blood. With this attitude, Sioux Technologies started building a multidisciplinary system house in China a few years ago. The Chinese high-tech industry is growing at a rapid pace and Sioux in Suzhou now employs around 100 people working for Western and Chinese customers. Slowly a second Sioux is emerging in which all competences are…